Page last updated: 2024-10-31

mitoxantrone and African Lymphoma

mitoxantrone has been researched along with African Lymphoma in 7 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43."1.48Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Witiak, DT1
Kamat, PL1
Allison, DL1
Liebowitz, SM1
Glaser, R1
Holliday, JE1
Moeschberger, ML1
Schaller, JP1
Faizan, M1
Anwar, S1
Khan, S1
Plasschaert, SL1
van der Kolk, DM1
de Bont, ES1
Kamps, WA1
Morisaki, K1
Bates, SE1
Scheffer, GL1
Scheper, RJ1
Vellenga, E1
de Vries, EG1
Mantzios, G1
Tsirigotis, P1
Veliou, F1
Boutsikakis, I1
Petraki, L1
Kolovos, J1
Papageorgiou, S1
Robos, Y1
van Imhoff, GW1
van der Holt, B1
MacKenzie, MA1
Ossenkoppele, GJ1
Wijermans, PW1
Kramer, MH1
van 't Veer, MB1
Schouten, HC1
van Marwijk Kooy, M1
van Oers, MH1
Raemaekers, JM1
Sonneveld, P1
Meulendijks, LA1
Kluin, PM1
Kluin-Nelemans, HC1
Verdonck, LF1
Chow, KU1
Sommerlad, WD1
Boehrer, S1
Schneider, B1
Seipelt, G1
Rummel, MJ1
Hoelzer, D1
Mitrou, PS1
Weidmann, E1
Ohnuma, T1
Arkin, H1
Holland, JF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352]Phase 222 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Response

Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months

Interventionmonths (Median)
Bendamustine/Ofatumumab5.6

Number of Patients With a Complete Response

Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab7

Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety

A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab16

Overall Response (OR)

Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab19

Overall Survival (OS)

Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months

Interventionmonths (Median)
Bendamustine/Ofatumumab12.0

Progression-free Survival

Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Interventionmonths (Median)
Bendamustine/Ofatumumab8.6

Time to Progression (TTP)

Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Interventionmonths (Median)
Bendamustine/Ofatumumab10.5

Reviews

1 review available for mitoxantrone and African Lymphoma

ArticleYear
Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature.
    Annals of hematology, 2004, Volume: 83, Issue:7

    Topics: Addison Disease; Adrenal Cortex Neoplasms; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe

2004

Trials

1 trial available for mitoxantrone and African Lymphoma

ArticleYear
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
    Leukemia, 2005, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag

2005

Other Studies

5 other studies available for mitoxantrone and African Lymphoma

ArticleYear
Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
    Journal of medicinal chemistry, 1983, Volume: 26, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzoquinones; Burkitt Lymphoma; Cell Line; Cisplatin; Drug Resistan

1983
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo

2018
The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-01, Volume: 9, Issue:14

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transpo

2003
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Haematologica, 2002, Volume: 87, Issue:1

    Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Der

2002
Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect).
    British journal of cancer, 1986, Volume: 54, Issue:3

    Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Carboplatin; Cell Count; Cell Survival; Cisplati

1986
chemdatabank.com